Nivolumab Can Still Benefit RCC Patients Who Stop Due to Immune-Related Toxicity

A small study found that patients with metastatic renal cell carcinoma (mRCC) who discontinue nivolumab due to immune-related adverse events can continue to derive benefit even after cessation of therapy.

Source: CancerNetwork - November 6, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Genitourinary Cancers Conferences/IKCS 2016 Kidney Cancer News Source Type: news